ANAVEX LIFE SCIENCES CORP. - COMMON STOCK

Anavex Life Sciences to Announce Fiscal 2025 First Quarter Financial Results on Wednesday, February 12, 2025

05 2 2025 06:30:00 提供 Nasdaq GlobeNewswire

Anavex Life Sciences Announces Issuance of Blarcamesine (ANAVEX®2-73) Composition of Matter U.S. Patent Expanding its Intellectual Property Portfolio

27 1 2025 06:30:00 提供 Nasdaq GlobeNewswire

Anavex Life Sciences Announces Peer-Reviewed Publication of Oral Blarcamesine Phase IIb/III Data in The Journal of Prevention of Alzheimer’s Disease

15 1 2025 06:30:00 提供 Nasdaq GlobeNewswire

New Phase IIb/III Clinical Data Demonstrates Over Three Years of Continuous Treatment with Oral Blarcamesine to Significantly Benefit Early Alzheimer’s Disease Patients

13 1 2025 06:30:00 提供 Nasdaq GlobeNewswire

Anavex Life Sciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference

06 1 2025 06:30:00 提供 Nasdaq GlobeNewswire

NetDania - New 12 months High: ANAVEX LIFE SCIENCES CORP. - COMMON STOCK

26 12 2024 11:00:28 提供 NetDania Notify

NetDania - New 12 months High: ANAVEX LIFE SCIENCES CORP. - COMMON STOCK

24 12 2024 08:45:04 提供 NetDania Notify

NetDania - New 12 months High: ANAVEX LIFE SCIENCES CORP. - COMMON STOCK

23 12 2024 08:57:16 提供 NetDania Notify

Anavex Life Sciences Reports Fiscal 2024 Fourth Quarter Financial Results and Provides Business Update

23 12 2024 06:30:00 提供 Nasdaq GlobeNewswire

Blarcamesine Receives EMA Filing Acceptance for Treatment of Alzheimer’s Disease

23 12 2024 06:00:00 提供 Nasdaq GlobeNewswire

Anavex Life Sciences to Announce Fiscal 2024 Fourth Quarter Financial Results on Monday, December 23, 2024

16 12 2024 06:30:00 提供 Nasdaq GlobeNewswire

Anavex Life Sciences to Report New Long-Term Oral Blarcamesine Phase IIb/III Alzheimer’s Disease Data at J.P. Morgan 2025 Healthcare Conference

09 12 2024 06:30:00 提供 Nasdaq GlobeNewswire

Anavex Life Sciences to Present at the 7th Annual Evercore ISI HealthCONx Conference 2024

02 12 2024 06:30:00 提供 Nasdaq GlobeNewswire

Anavex Life Sciences Announces Submission of Blarcamesine MAA for Treatment of Alzheimer’s Disease to EMA

26 11 2024 06:30:00 提供 Nasdaq GlobeNewswire

Anavex Life Sciences Announces Acceptance of Peer-Reviewed Manuscript of Oral Blarcamesine Phase IIb/III Data in a Reference Alzheimer’s Disease Journal

25 11 2024 06:30:00 提供 Nasdaq GlobeNewswire

Anavex’s Blarcamesine Achieves Pre-specified Efficacy in Phase IIb/III Alzheimer’s Trial: Data Presented at CTAD Conference 2024

31 10 2024 03:00:00 提供 Nasdaq GlobeNewswire

Anavex Life Sciences Announces Encouraging Preliminary Biomarker Results from Ongoing Phase 2 Study of ANAVEX®3-71 for the Treatment of Schizophrenia

17 10 2024 06:30:00 提供 Nasdaq GlobeNewswire

Anavex Life Sciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference 2024

03 9 2024 06:30:00 提供 Nasdaq GlobeNewswire

Anavex Life Sciences Reports Fiscal 2024 Third Quarter Financial Results and Provides Business Update

06 8 2024 06:30:00 提供 Nasdaq GlobeNewswire

Anavex Life Sciences to Announce Fiscal 2024 Third Quarter Financial Results on Tuesday, August 6, 2024

01 8 2024 06:30:00 提供 Nasdaq GlobeNewswire